tiprankstipranks

Organovo Holdings Completes FXR Program Sale to Eli Lilly

Story Highlights
Organovo Holdings Completes FXR Program Sale to Eli Lilly

Organovo Holdings ( (ONVO) ) has shared an update.

On March 25, 2025, Organovo Holdings, Inc. completed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company. The transaction, which was initially disclosed on February 25, 2025, involved an upfront cash payment of $10 million, with potential milestone payments of up to $50 million contingent on future achievements. This strategic move allows Lilly to acquire all commercial and intellectual property rights for worldwide development, while Organovo benefits from the financial influx and potential future earnings. Additionally, Vaidehi Joshi resigned from Organovo’s Board on March 21, 2025, with no disagreements cited.

More about Organovo Holdings

Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD). The company utilizes proprietary technology to create three-dimensional (3D) human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.

YTD Price Performance: -48.55%

Average Trading Volume: 679,045

Technical Sentiment Signal: Buy

Current Market Cap: $4.83M

Find detailed analytics on ONVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App